381233-75-6

Basic information

• Product Name: 5-BROMO-3-IODO-PYRIDIN-2-OL
• Synonyms: 5-Bromo-2-hydroxy-3-iodopyridine;2(1H)-Pyridinone, 5-broMo-3-iodo-;5-BroMo-3-iodo-1H-pyridin-2-one;5-BroMo-3-iodo-2-hydroxypyridine, 97%;5-BroMo-3-iodopyridin-2(1H)-one;5‐bromo‐3‐iodo‐1,2‐dihydropyridin‐2‐one
• CAS NO: 381233-75-6
• Molecular Formula: C₅H₃BrINO
• Molecular Weight: 299.9
• Mol File: 381233-75-6.mol

Chemical Properties

• Melting Point: 226-227℃
• Boiling Point: 316.3°Cat760mmHg
• Flash Point: 145.1°C
• Appearance: /
• Density: 2.512g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.714
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.52±0.10(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 5-BROMO-3-IODO-PYRIDIN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-IODO-PYRIDIN-2-OL(381233-75-6)
• EPA Substance Registry System: 5-BROMO-3-IODO-PYRIDIN-2-OL(381233-75-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 381233-75-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-IODO-PYRIDIN-2-OL is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to be incorporated into molecules with potential therapeutic effects. Its unique substitution pattern allows for the creation of new drug candidates that can address unmet medical needs.
Used in Agrochemical Industry:
In the agrochemical sector, 5-BROMO-3-IODO-PYRIDIN-2-OL is utilized as a building block for the development of novel agrochemicals, such as pesticides, leveraging its pesticidal properties to enhance crop protection and yield.
Used in Organic Synthesis:
5-BROMO-3-IODO-PYRIDIN-2-OL is employed as a versatile building block in organic synthesis, where its reactivity and structural features are harnessed to construct complex organic molecules for various applications, including but not limited to medicinal chemistry and material science.

InChI:InChI=1/C5H3BrINO/c6-3-1-4(7)5(9)8-2-3/h1-2H,(H,8,9)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 13466-38-1 5-bromopyridin-2-ol 

Downstream Products

• 942589-70-0 5-bromo-3-((trimethylsilyl)ethynyl)pyridin-2-ol 
• 942589-70-0 5-bromo-3-[(trimethylsilyl)ethynyl]-2(1H)-pyridinone 
• 1215107-69-9 methyl 2-(4-fluorophenyl)-5-(2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)furo[2,3-b]pyridine-3-carboxylate 
• 1215107-67-7 5-(2-chloro-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)furo[2,3-b]pyridine-3-carboxylic acid 
• 1215107-09-7 tert-butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoate 
• 1215107-08-6 5-(5-(tert-butoxycarbonyl)-2-methylphenyl)-2-(4-fluorophenyl)furo[2,3-b]pyridine-3-carboxylic acid 
• 1215107-06-4 methyl 5-(5-(tert-butoxycarbonyl)-2-methylphenyl)-2-(4-fluorophenyl)furo[2,3-b]pyridine-3-carboxylate 
• 1215107-05-3 tert-butyl 3-(3-bromo-2-(4-fluorophenyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoate 
• 1215105-51-3 2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)furo[2,3-b]pyridine-3-carboxamide 
• 1301186-18-4 2-(4-fluorophenyl)-5-(2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)furo[2,3-b]pyridine-3-carboxylic acid 
• 1215107-04-2 3-(2-(4-fluorophenyl)-3-(methoxycarbonyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoic acid 
• 1215107-03-1 3-(3-bromo-2-(4-fluorophenyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoic acid 
• 1215107-02-0 methyl 3-(3-bromo-2-(4-fluorophenyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoate 
• 1215107-01-9 methyl 3-(2-(4-fluorophenyl)furo[2,3-b]pyridin-5-yl)-4-methylbenzoate 

Relevant articles and documents

PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

BCL-2 FAMILY PROTEINS MODULATING COMPOUNDS FOR CANCER TREATMENT

The present invention relates to compounds, compositions and methods for treating cancers and disorders of cell proliferation and more particularly, methods of making and using compounds that modulate at least one of the proteins chosen from Bcl-2, Mcl-1,

Br vs. TsO Chemoselective Suzuki–Miyaura Cross-Coupling Reaction on Nicotinaldehyde Moiety for the Preparation of 2,3,5-Trisubstituted Pyridines

Br vs. TsO chemoselective pallado-catalyzed Suzuki–Miyaura reaction has been developed from the 5-bromo-2-tosyloxynicotinaldehyde for the preparation of polysubstituted pyridines. This methodology has been applied for the preparation of a terpyridine alde

URAT1 inhibitor and its application

The invention discloses a URAT1 inhibitor compound and its application of the compound. The URAT1 inhibitor compound is the compound or its pharmaceutically acceptable salt shown in structure of Formula (I). The experiment shows that the compound provided

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies

Apoptosis control defects such as the deregulation of Bcl-2 family member expression are frequently involved in chemoresistance. In ovarian carcinoma, we previously demonstrated that Bcl-xL and Mcl-1 cooperate to protect cancer cells against ap

MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT

The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer : Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, 1 are as defined in claim 1

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A) : or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile (Perampanel): A novel, noncompetitive α-amino-3-hydroxy-5- methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist

Dysfunction of glutamatergic neurotransmission has been implicated in the pathogenesis of epilepsy and numerous other neurological diseases. Here we describe the discovery of a series of 1,3,5-triaryl-1H-pyridin-2-one derivatives as noncompetitive antagonists of AMPA-type ionotropic glutamate receptors. The structure-activity relationships for this series of compounds were investigated by manipulating individual aromatic rings located at positions 1, 3, and 5 of the pyridone ring. This culminated in the discovery of 2-(2-oxo-1-phenyl-5- pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel, 6), a novel, noncompetitive AMPA receptor antagonist that showed potent activity in an in vitro AMPA-induced Ca2+ influx assay (IC50 = 60 nM) and in an in vivo AMPA-induced seizure model (minimum effective dose of 2 mg/kg po). Perampanel is currently in regulatory submission for partial-onset seizures associated with epilepsy.

Synthetic approach to the chemical isostere of o -methyl honokiol

We established a synthetic method for the chemical isostere of the structurally unique natural product, 4-O-methyl honokiol by replacing two allyl groups with two different alkyl groups with the aim of developing synthetic analogues of the chemical isoste